Yonehiro Grant 4

Accession 0001193125-25-321148

CIK 0001641281other

View on SEC.gov Company Profile

Filed

Dec 15, 7:00 PM ET

Accepted

Dec 16, 5:11 PM ET

Size

55.2 KB

Accession

0001193125-25-321148

Insider Transaction Report

Form 4

Period: 2025-12-12

Bolt Biotherapeutics, Inc.BOLT

Yonehiro Grant

Chief Operating Officer

Transactions

Award
Employee Stock Option (Right to Buy)
2025-12-12+3,214→ 3,214 total
Exercise: $5.44Exp: 2027-01-17→ Common Stock (3,214 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−3,214→ 0 total
Exercise: $42.00Exp: 2027-01-17→ Common Stock (3,214 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+660→ 660 total
Exercise: $5.44Exp: 2028-01-16→ Common Stock (660 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−660→ 0 total
Exercise: $40.60Exp: 2028-01-17→ Common Stock (660 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+822→ 822 total
Exercise: $5.44Exp: 2028-04-03→ Common Stock (822 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−822→ 0 total
Exercise: $40.60Exp: 2028-04-03→ Common Stock (822 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+1,653→ 1,653 total
Exercise: $5.44Exp: 2029-01-10→ Common Stock (1,653 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−1,653→ 0 total
Exercise: $44.80Exp: 2029-01-10→ Common Stock (1,653 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+4,642→ 4,642 total
Exercise: $5.44Exp: 2029-11-12→ Common Stock (4,642 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−4,642→ 0 total
Exercise: $54.60Exp: 2029-11-12→ Common Stock (4,642 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+2,142→ 2,142 total
Exercise: $5.44Exp: 2030-09-02→ Common Stock (2,142 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−2,142→ 0 total
Exercise: $86.80Exp: 2030-09-02→ Common Stock (2,142 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+4,999→ 4,999 total
Exercise: $5.44Exp: 2031-02-03→ Common Stock (4,999 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−4,999→ 0 total
Exercise: $400.00Exp: 2031-02-03→ Common Stock (4,999 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+9,499→ 9,499 total
Exercise: $5.44Exp: 2032-02-17→ Common Stock (9,499 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−9,499→ 0 total
Exercise: $61.60Exp: 2032-02-17→ Common Stock (9,499 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+11,399→ 11,399 total
Exercise: $5.44Exp: 2033-02-26→ Common Stock (11,399 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−11,399→ 0 total
Exercise: $31.80Exp: 2033-02-26→ Common Stock (11,399 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+11,749→ 11,749 total
Exercise: $5.44Exp: 2034-03-03→ Common Stock (11,749 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−11,749→ 0 total
Exercise: $25.40Exp: 2034-03-03→ Common Stock (11,749 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+7,749→ 7,749 total
Exercise: $5.44Exp: 2034-07-22→ Common Stock (7,749 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−7,749→ 0 total
Exercise: $14.60Exp: 2034-07-22→ Common Stock (7,749 underlying)
Award
Employee Stock Option (Right to Buy)
2025-12-12+17,499→ 17,499 total
Exercise: $5.44Exp: 2035-04-30→ Common Stock (17,499 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-12-12−17,499→ 0 total
Exercise: $7.02Exp: 2035-04-30→ Common Stock (17,499 underlying)

Footnotes (17)

[F1]The option is fully vested and exercisable.
[F10]For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023.
[F11]The reporting person agreed to cancellation of an option granted on February 27, 2023, in exchange for a new option having a lower exercise price.
[F12]For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024.
[F13]The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price.
[F14]For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024.
[F15]The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price.
[F16]For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025.
[F17]The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.
[F2]The reporting person agreed to cancellation of an option granted on January 18, 2017, in exchange for a new option having a lower price.
[F3]The reporting person agree to cancellation of an option granted on January 17, 2018, in exchange for a new option having a lower exercise price.
[F4]The reporting person agreed to cancellation of an option granted on April 4, 2018, in exchange for a new option having a lower exercise price.
[F5]The reporting person agreed to cancellation of an option granted on January 11, 2019, in exchange for a new option having a lower exercise price.
[F6]The reporting person agreed to cancellation of an option granted on November 13, 2019, in exchange for a new option having a lower exercise price.
[F7]The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price.
[F8]The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price.
[F9]The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Bolt Biotherapeutics, Inc.

CIK 0001641281

→

Entity typeother

Related Parties

filerCIK 0001428666

Filing Metadata

Form type: 4
Filed: Dec 15, 7:00 PM ET
Accepted: Dec 16, 5:11 PM ET
Size: 55.2 KB

View on SEC.gov